aTyr Pharma Publishes Preclinical Anti-Fibrosis Data on ATYR0101
The company reported preclinical anti-fibrotic effects for ATYR0101 and said the program is in IND-enabling studies, with clinic entry expected in 2027.
The company reported preclinical anti-fibrotic effects for ATYR0101 and said the program is in IND-enabling studies, with clinic entry expected in 2027.